pfizer_logo

Pfizer to call off $160 billion merger with Allergan

pharmafile | April 6, 2016 | News story | Business Services, Research and Development, Sales and Marketing |ย ย Allergan, Pfizer, deal, legal, merger and acquisition, regulationย 

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: AGN) according to reports, ending the biggest pharma deal as the US lawmakers take to enforcing stricter rules for corporations trying to dodge taxes.

The proposed regulations were announced on Monday by the Treasury Department with the aim to cut transactions that aid inversions for the corporates if there have been other similar deals over the past 36 months. For the same period, Allergan has had several similar acquisitions.

Following the termination, Pficer will be required to pay a $400 million fee to Allergan for expenses relating to the deal.

Advertisement

In November, Ireland-headquarter Allergan agreed to merge with Pfizer in a deal to great the largest healthcare entity in the world. The deal would have also brought down the effective tax rate for Pfizer.

The two companies are likely to make a joint announcement terminating the deal on Wednesday.

Anjali Shukla

Related Content

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …

The Gateway to Local Adoption Series

Latest content